TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07800871: FT839 in Autoimmune Diseases

Sponsor: Fate Therapeutics · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 446 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07800871 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07800871 Rescue Dossier →